Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| Nilotinib | Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM. It is under investigation as a possible treatment for chronic myelogenous leukemia (CML). Group: Pharmaceutical. CAS No. 641571-10-0. Pack Sizes: 10 g. Product ID: B0084-074229. Molecular formula: Custom synthesis is available. Send your inquiries for more information. |  London |
| Nilotinib Impurities | Nilotinib Impurities are essential constituents in the domain of quality control, intricately involved in the refinement and enhancement of nilotinib, a therapeutic agent for chronic myeloid leukemia. Their significance lies in facilitating the detection and minimization of undesirable variants, thus ensuring the drug's safety and potency during pharmaceutical synthesis. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Nilotinib monohydrochloride monohydrate | Nilotinib monohydrochloride monohydrate is an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. It binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. It also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). Uses: Tyrosine kinase inhibitors. Group: Pharmaceutical. CAS No. 923288-90-8. Pack Sizes: 100 mg. Product ID: B0084-182383. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 3-(5-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzenamine | An impurity of Nilotinib, which is a Bcr-Abl inhibitor with IC50 less than 36 nM. Group: Pharmaceutical. CAS No. 641571-16-6. Pack Sizes: 10 mg. Product ID: B1416-478156. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Radotinib | Radotinib, also known as IY-5511, is an orally available, hydrochloride salt form of radotinib, a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome-positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways. The inhibitory effect of radotinib on these specific tyrosine kinases may decrease cellular proliferation and inhibit angiogenesis. This agent has shown potent efficacy in CML cells that are resistant to the first-generation standard tyrosine kinase inhibitors, such as imatinib, nilotinib and dasatinib. PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. Check for active clinical trials or closed clinical trials using this agent. Group: Pharmaceutical. CAS No. 926037-48-1. Pack Sizes: 50 mg. Product ID: B0084-465339. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
